NCT02608268 2023-12-06
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Novartis
Phase 1/2 Terminated
Novartis
Roswell Park Cancer Institute
Zhejiang Cancer Hospital
National Cancer Institute (NCI)
M.D. Anderson Cancer Center